GENEDRIVE PLC — Report Publication Announcement 2017

Mar 24, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3252A

Genedrive PLC

24 March 2017

RNS  

For release: 24 March 2017

genedrive plc ("genedrive" or the "Company")

Notice of Interim Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ended 31 December 2016 on Thursday, 30 March 2017.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                               +44 (0)161 989 0245

Matthew Fowler: Finance Director

Peel Hunt LLP

James Steel                                                                                                                        +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

Notes to Editors

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORPGUMGWUPMGGW